George Browne (violetbelt26)

To examine, 1) optimal structure of break periods to mitigate physiological heat strain during rugby league play (Stage 1); and ii) effectiveness of three different cooling strategies applied during breaks (Stage 2). Counter-balanced crossover design. In 37 °C, 50% RH, 11 males completed six simulated 80-min (two 40-min halves) rugby league matches on a treadmill with different break structures regular game (RG) (12-min halftime), 1-min or 3-min "quarter-time" breaks halfway through each half with a 12-min halftime break (R1C and R3C), a 20-min halftime break (EH), or 1-min or 3-min quarter-time breaks with a 20-min halftime break (E1C and E3C) [Stage 1]. Nine participants completed Stage 2, which assessed the application of either ice towels (ICE), an electric fan (FAN) or a misting fan (MST) during breaks in the E3C protocol which, in Stage 1, prevailed as the optimal break structure. Stage 1 Irrespective of quarter-time break duration, reductions in rectal temperature (-0.24 °C ± 0.24) and heart rate (-61 ± 10 bpm) during the halftime break were greater with a 20-min compared to a 12-min break (-0.08 ± 0.13 °C, p = 0.005; -55 ± -9 bpm, p = 0.021). Stage 2 End-game rises in rectal temperature were smaller (p < 0.006) in MST (1.41 ± 0.22 °C), FAN (1.55 ± 0.36 °C) and ICE (1.60 ± 0.21 °C) than in CON (1.80 ± 0.39 °C). DJ4 The end-halftime heart rate was lower (p < 0.001) in ICE (89 ± 13 bpm), MST (90 ± 10 bpm) and FAN (92 ± 13 bpm) than in CON (99 ± 18 bpm). Combining an extended halftime period and quarter-time breaks with MST application is the optimal cooling strategy for rugby league players in hot, humid conditions. Combining an extended halftime period and quarter-time breaks with MST application is the optimal cooling strategy for rugby league players in hot, humid conditions. Few studies have evaluated real-world effectiveness of lenvatinib (Len)/everolimus (Eve) for advanced/metastatic renal cell carcinoma (a/mRCC). This study evaluated patient profiles and clinical outcomes of second- and subsequent-line (≥ 2L) Len/Eve for a/mRCC. A longitudinal retrospective study examined adult patients initiating ≥ 2L Len/Eve for a/mRCC from May 13, 2016, to July 31, 2019. Len/Eve clinical trial participants or those treated for other primary tumors were excluded. Outcomes included objective response rate, duration of response, progression-free survival (PFS), time to treatment discontinuation, and overall survival. Time-to-event outcomes were estimated using Kaplan-Meier methods. Seventy-nine patients were assessed the median age was 64.8 years, 78.5% were Caucasian, 73.4% were male, 78.5% had an Eastern Cooperative Oncology Group performance status score of 0/1, 29.1% received 2L/3L Len/Eve, and the median number of prior lines of therapy was 3 (range, 1-8). At initial diagnosis, 55.7retrospective study, Len/Eve showed real-world effectiveness in clinical practice in a heavily pretreated a/mRCC patient population. Suboptimal completion of chemotherapy, which may involve reduced patient adherence, remains a serious issue and leads to reduced treatment efficacy. This study assessed the completion rates, risk factors for noncompletion, and cost impact for noncompletion in patients on capecitabine monotherapy (Cape) or capecitabine with oxaliplatin (CAPOX) for the adjuvant treatment of early-stage colon cancer. Patients with a diagnosis of early-stage colon cancer between April 2013 and March 2017 were retrospectively identified. Treatment completion was evaluated. Multivariate logistic regressions analyses were used to assess the baseline factors associated with noncompletion. Adverse events, costs, healthcare resource utilization, and cost impact for noncompletion were investigated. A total of 673 patients met the eligibility criteria, of which 382 (57%) were treated with Cape and 291 (43%) with CAPOX. The ove